Literature DB >> 34978027

Selectivity of the P2X3 receptor antagonist Eliapixant, and its potential use in the treatment of endometriosis.

Michelle C Fletcher1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34978027      PMCID： PMC8850518          DOI： 10.1007/s11302-021-09831-5

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN： 1573-9538            Impact factor:   3.950


× No keyword cloud information.
  10 in total

1.  P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP.

Authors:  Debra A Cockayne; Philip M Dunn; Yu Zhong; Weifang Rong; Sara G Hamilton; Gillian E Knight; Huai-Zhen Ruan; Bei Ma; Ping Yip; Philip Nunn; Stephen B McMahon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  J Physiol       Date:  2005-06-16       Impact factor: 5.182

2.  Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation.

Authors:  David Richards; Joel R Gever; Anthony P Ford; Samuel J Fountain
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

3.  Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.

Authors:  Jaclyn A Smith; Michael M Kitt; Alyn H Morice; Surinder S Birring; Lorcan P McGarvey; Mandel R Sher; Yu-Ping Li; Wen-Chi Wu; Zhi Jin Xu; David R Muccino; Anthony P Ford
Journal:  Lancet Respir Med       Date:  2020-02-25       Impact factor: 30.700

4.  Immunocytochemical localization of P2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injury.

Authors:  S D Novakovic; L C Kassotakis; I B Oglesby; J A Smith; R M Eglen; A P Ford; J C Hunter
Journal:  Pain       Date:  1999-03       Impact factor: 6.961

5.  Purinergic receptors in the carotid body as a new drug target for controlling hypertension.

Authors:  Wioletta Pijacka; Davi J A Moraes; Laura E K Ratcliffe; Angus K Nightingale; Emma C Hart; Melina P da Silva; Benedito H Machado; Fiona D McBryde; Ana P Abdala; Anthony P Ford; Julian F R Paton
Journal:  Nat Med       Date:  2016-09-05       Impact factor: 53.440

6.  Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice.

Authors:  D A Cockayne; S G Hamilton; Q M Zhu; P M Dunn; Y Zhong; S Novakovic; A B Malmberg; G Cain; A Berson; L Kassotakis; L Hedley; W G Lachnit; G Burnstock; S B McMahon; A P Ford
Journal:  Nature       Date:  2000-10-26       Impact factor: 49.962

7.  Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers.

Authors:  Adam J Davenport; Ioana Neagoe; Nico Bräuer; Markus Koch; Andrea Rotgeri; Jens Nagel; Alexis Laux-Biehlmann; Frederic Machet; Anne-Marie Coelho; Susan Boyce; Nikisha Carty; Mark J Gemkow; Stephen D Hess; Thomas M Zollner; Oliver M Fischer
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

8.  P2X3 receptor involvement in endometriosis pain via ERK signaling pathway.

Authors:  Shaojie Ding; Libo Zhu; Yonghong Tian; Tianhong Zhu; Xiufeng Huang; Xinmei Zhang
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

9.  Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.

Authors:  Alyn Morice; Jaclyn A Smith; Lorcan McGarvey; Surinder S Birring; Sean M Parker; Alice Turner; Thomas Hummel; Isabella Gashaw; Lueder Fels; Stefan Klein; Klaus Francke; Christian Friedrich
Journal:  Eur Respir J       Date:  2021-11-18       Impact factor: 16.671
  10 in total
  1 in total

Review 1.  The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.

Authors:  Seunga Han; Haruna Suzuki-Kerr; Srdjan M Vlajkovic; Peter R Thorne
Journal:  Purinergic Signal       Date:  2022-09-29       Impact factor: 3.950
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.